Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

Ipsen is offering $1.45 per share for Cambridge ... sales for top-selling acromegaly and neuroendocrine tumour therapy Somatuline (lanreotide). Tazverik is a first-in-class EZH2a inhibitor ...

INR:9688. bubble fresh frults Ipsen's acromegaly treatment drug lanreotide acetate sustained-release injection (prefilled) approved U.S. officials say high te ...